FAS and ovarian carcinoma: This was confirmed at the gene-specific level in a study by Cacan and co-workers, who showed that the enrichment of acetylated histone H3 was significantly lower at the FAS promoter in cisplatin-resistant A2780-AD ovarian cancer cells compared with chemo-sensitive A2780 cells, suggesting that the loss of FAS expression due to low acetylation contributes to cisplatin resistance [112].